The stock price of Heron Therapeutics Inc (NASDAQ: HRTX) has surged by 13.62 when compared to previous closing price of 2.13, but the company has seen a 3.42% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-06 that Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel – Executive Director, Legal Craig Collard – Chief Executive Officer Ira Duarte – Executive Vice President, Chief Financial Officer Conference Call Participants Yuxi Dong – Jefferies Serge Belanger – Needham & Company Carl Byrnes – Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call.
Is It Worth Investing in Heron Therapeutics Inc (NASDAQ: HRTX) Right Now?
The 36-month beta value for HRTX is at 1.27. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HRTX is 150.92M, and currently, shorts hold a 21.84% of that float. The average trading volume for HRTX on May 07, 2025 was 1.78M shares.
HRTX’s Market Performance
HRTX’s stock has seen a 3.42% increase for the week, with a 15.24% rise in the past month and a 33.70% gain in the past quarter. The volatility ratio for the week is 10.24%, and the volatility levels for the past 30 days are at 8.38% for Heron Therapeutics Inc The simple moving average for the past 20 days is 15.07% for HRTX’s stock, with a 25.90% simple moving average for the past 200 days.
Analysts’ Opinion of HRTX
Many brokerage firms have already submitted their reports for HRTX stocks, with Rodman & Renshaw repeating the rating for HRTX by listing it as a “Buy.” The predicted price for HRTX in the upcoming period, according to Rodman & Renshaw is $7 based on the research report published on June 13, 2024 of the previous year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see HRTX reach a price target of $6. The rating they have provided for HRTX stocks is “Overweight” according to the report published on April 23rd, 2024.
Needham gave a rating of “Buy” to HRTX, setting the target price at $5 in the report published on March 13th of the previous year.
HRTX Trading at 10.05% from the 50-Day Moving Average
After a stumble in the market that brought HRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.42% of loss for the given period.
Volatility was left at 8.38%, however, over the last 30 days, the volatility rate increased by 10.24%, as shares surge +23.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.72% upper at present.
During the last 5 trading sessions, HRTX rose by +3.42%, which changed the moving average for the period of 200-days by -27.33% in comparison to the 20-day moving average, which settled at $2.10. In addition, Heron Therapeutics Inc saw 58.17% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for HRTX
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.69 for the gross margin
The net margin for Heron Therapeutics Inc stands at -0.09. The total capital return value is set at -0.08.
Based on Heron Therapeutics Inc (HRTX), the company’s capital structure generated 1.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.13.
Currently, EBITDA for the company is -5.06 million with net debt to EBITDA at -26.96. When we switch over and look at the enterprise to sales, we see a ratio of 3.39. The receivables turnover for the company is 1.95for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.29.
Conclusion
In conclusion, Heron Therapeutics Inc (HRTX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
